- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo SR, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; 135(10):e146-603.
- Cardiovascular diseases (CVDs). World Health Organization. Available at: URL: http://www.who.int/
en/news-room/fact-sheets/detail/cardiovascular-diseases-
(cvds); 2017.
- Hatmi Z, Tahvildari S, Motlag AG, Kashani AS. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord. 2007; 7(1):32.
- Cardiac death status in Iran. Tabnak. Available at: URL: https://www.tabnak.ir/fa/news/838094; 2008.
- Sidney S, Quesenberry CP, Jaffe MG, Sorel M, Nguyen-Huynh MN, Kushi LH, et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 2016; 1(5):594-9.
- Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal medications in cardiovascular medicine. J Am Coll Cardiol. 2017; 69(9):1188-99.
- Fallah Huseini H, Hemati AR, Alavian SM. A review of herbal medicine: Silybum marianum. J Med Plants. 2004; 3(11):14-24.
- Lorenz D, Lücker P, Mennicke W, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exper Clin Pharmacol. 1984; 6(10):655-61.
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1):1.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996; 17(1):1-12.
- Fallah Huseini H, Larijani B, Fakhrzadeh H, Radjabipour B, Akhondzadeh S, Toliat T, et al. The clinical trial of silybum marianum seed extract (silymarin). Iran J Diabetes Lipid Disord. 2004; 3(2):201-6.
- Nassuato G, Iemmolo R, Strazzabosco M, Lirussi F, Deana R, Francesconi M, et al. Effect of Silibinin on biliary lipid composition experimental and clinical study. J Hepatol. 1991; 12(3):290-5.
- Di Pierro F, Putignano P, Ferrara T, Raiola C, Rapacioli G, Villanova N. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia. Clin Pharmacol Adv Appl. 2017; 9:1.
- Di Pierro F, Bellone I, Rapacioli G, Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndrome Obesity. 2015; 8:89.
- Giuseppe D, Angela DA, Davide R, Pamela M. Effects of a combination of berberis aristata, silybum marianum and monacolin on lipid profile in subjects at low cardiovascular risk; a double-blind, randomized, placebo-controlled trial. Int J Mol Sci. 2017; 18(2):343.
- Derosa G, Romano D, D'Angelo A, Maffioli
P. Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine. 2015; 22(2):231-7.
- Derosa G, Bonaventura A, Bianchi L, Romano D, D'angelo A, Fogari E, et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Exp Opin Biol Ther. 2013; 13(11):1495-506.
- Ebrahimpour-Koujan S, Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn.(silymarin) extract supplement: a triple-blinded randomized controlled clinical trial. Phytomedicine. 2018; 44:39-44.
- Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007; 6(2):146-57.
- Škottová N, Krečman V. Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Olomuc Facul Med. 1998; 141:39-40.
- Škottová N, Krečman V. Silymarin as a potential hypocholesterolaemic drug. Physiol Res. 1998; 47(1):1-7.
- Kazazis CE, Evangelopoulos AA, Kollas A, Vallianou NG. The therapeutic potential of milk thistle in diabetes. Rev Diabetic Stud. 2014; 11(2):167.
- Malekinejad H, Rezabakhsh A, Rahmani F, Hobbenaghi R. Silymarin regulates the cytochrome P450 3A2 and glutathione peroxides in the liver of streptozotocin-induced diabetic rats. Phytomedicine. 2012; 19(7):583-90.
- Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta B, et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000; 7(1):21-4.
- Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008; 68(6):2043-50.
- Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, et al. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer’s disease. Neurobiol Aging. 2015; 36(5):1792-807.
- Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps Pharm. 2011; 12(2):705-11.
- Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013; 79(6):437-46.
|
